Key result
High-intensity statin use remains low post-ACS with only ~16% of patients treated at one year.
Observational (n=7,802)
Yes
Utilization of high-intensity statins following an acute coronary syndrome event remains significantly lower than guideline recommendations in real-world practice.
Answers are grounded in this paper and cite their sources.
Suboptimal high-intensity statin use persists after ACS in real-world care; leaves open effective strategies to close this guideline gap.
PURPOSE: High-intensity statins (HIS) are recommended by current treatment guidelines for patients with clinical atherosclerotic cardiovascular disease and should be administered soon after an acute coronary syndrome (ACS) event and maintained thereafter. However, adherence to guidelines remains adequate. Statin utilization patterns during index hospitalization and the first year after ACS event, and the association between statin utilization and post-discharge clinical and economic outcomes, are described. METHODS: Retrospective, observational study of US adults from the MarketScan Research Databases (2002-2014) with ≥ 1 inpatient admission for ACS and no evidence of previous ACS event < 12 months prior to index. RESULTS: In total, 7802 patients met inclusion criteria. The most common index hospitalization primary diagnosis was myocardial infarction (94.6%). In the 3-month period before ACS admission, 3.4 and 14.9% of patients received HIS or low-to-moderate intensity statin, versus 13.2 and 30.7% during index hospitalization, and 16.4 and 45.1% in the year of follow-up. Of 1336 patients with a statin prescription filled on/after discharge, 53.2% filled prescriptions within 15 days of discharge and 14.9% delayed for > 91 days. The most common post-index hospital admissions for cardiovascular events were due to recurrent ACS (incidence rate = 115.2), heart failure (110.0), and revascularization (76.4). During follow-up, 2355 patients (30.2%) had all-cause inpatient admissions and 1136 (14.6%) had cardiovascular-specific admissions; mean all-cause medical and healthcare costs were $2456 and $2870, respectively, per patient per month. CONCLUSIONS: Statin dosing and utilization of HIS remains lower than recommended in current treatment guidelines, leaving patients at considerable risk of subsequent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Boklage et al. (2018) conducted an observational in Acute Coronary Syndrome (n=7,802). Statin therapy (High-intensity vs Low-to-moderate intensity) vs. No statin therapy was evaluated on High-intensity statin utilization in the year of follow-up. High-intensity statin utilization remained lower than recommended, with only 13.2% of patients receiving it during their index acute coronary syndrome hospitalization and 16.4% in the year of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: